Comparison of DNA topoisomerase IIα expression in small cell and nonsmall cell carcinoma of the lung: In search of a mechanism of chemotherapeutic response

Cancer

Volumn 78, Issue 4, 1996, Pages 729-735

  Guinee Jr , Donald G ^a,e   Holden, Joseph A ^a   Benfield, John R ^b   Woodward, Madeline L ^a   Przygodzki, Ronald M ^c   Fishback, Nancy F ^d   Koss, Michael N ^c   Travis, William D ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

chemotherapy; lung cancer; lung neoplasms; nonsmall cell carcinoma; small cell carcinoma; topoisomerase II

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE;

ARTICLE; CLINICAL ARTICLE; DNA REPLICATION; DRUG SENSITIVITY; ENZYME INDUCTION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LUNG NEOPLASMS; STAINING AND LABELING;

EID: 9444268744     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960815)78:4<729::AID-CNCR6>3.0.CO;2-9     Document Type: Article

References (59)

1. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995;75:191-202.
2. Hinson JA Jr., Perry MC. Small cell lung cancer. CA Cancer J Clin 1993;43:216-25.
3. Blackstein ME. Advances in chemotherapy for small cell lung cancer. Semin Oncol 1994;21:38-42.
4. Baylin SB, Abeloff MD, Goodwin G, Carney DN, Gazdar AF. Activities of L-dopa decarboxylase and diamine oxidase (histaminase) in human lung cancers and decarboxylase as a marker for small (oat) cell cancer in cell culture. Cancer Res 1980;40:1990-4.
5. Johnson DH, Hainsworth JD, Hande KR, Greco FA. Current status of etoposide in the management of small cell lung cancer. Cancer 1991;67:231-44.
6. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992;327:1434-41.
7. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989;58:351-75.
8. Zhang H. D'Arpa P, Liu LF. A model for tumor cell killing by topoisomerase poisons. Cancer Cells 1990;2:23-7.
9. Kohn KW, Jackman J, O'Connor PM. Cell cycle control and cancer chemotherapy. J Cell Biochem 1994;54:440-52.
10. Schneider E, Hsiang YH, Liu LF. DNA topoisomerases as anticancer drug targets. Adv Pharmacol 1990;21:149-83.
11. Deffie AM, Batra JK, Goldenberg GJ. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 1989;49:58-62.
12. Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, Yanagida M. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell 1987;50:917-25.
13. DiNardo S, Voelkel K, Sternglanz R. DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc Natl Acad Sci U S A 1984; 81:2616-20.
14. Holden JA, Rolfson DH, Wittwer CT. Human DNA topoisomerase II: evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry 1990;29:2127-34.
15. Chung TD, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA 1989;86:9431-5.
16. Hirsch FR, Matthews MJ, Aisner S. Histopathologic classification of small cell lung cancer. Changing concepts and terminology. Cancer 1988;62:973-7.
17. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
18. Robinson RG, Rapp L, Bowdish KJ, Graham MA, Huff AC, Coughlin SA. Isolation and characterization of monoclonal antibodies to a recombinant human topoisomerase II polypeptide. Hybridoma 1993;12:407-15.
19. Holden JA, Snow GW, Perkins SL, Jolies CJ, Kjeldsberg CR. Immunohistochemical staining for DNA topoisomerase II in frozen and formalin-fixed paraffin-embedded human tissues. Mod Pathol 1994;7:829-34.
20. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991; 39:741-8.
21. Holden JA, Perkins SL, Snow GW, Kjeldsberg CR. Immunohistochemical staining for DNA topoisomerase II in non-hodgkin's lymphomas. Am J Clin Pathol 1995;104:54-9.
22. Snedecor GW, Cochran WG. Statistical methods. Ames (IA): Iowa State University Press, 1967:114-6.
23. Guinee DG Jr., Fishback NF, Koss MN, Abbondanzo SL, Travis WD. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open lung biopsies. Am J Clin Pathol 1994; 102:406-14.
24. Anonymous. The World Health Organization histological typing of lung tumors. Am J Clin Pathol 1982;77:123-36.
25. Travis WD, Linnoila RI, Tsokos MG. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991;15:529-53.
26. Nitiss JL, Liu YX, Harbury P, Jannatipour M, Wasserman R, Wang JC. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res 1992;52:4467-72.
27. Davies SM, Robson CN, Davies SL, Hickson ID. Nuclear to-poisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 1988;263:17724-9.
28. Robinson MJ, Osheroff N. Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II. Biochemistry 1991;30:1807-13.
29. Long BH, Musial ST, Brattain MG. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide. Cancer Res 1986;46:3809-16.
30. Kasahara K, Fujiwara Y, Sugimoto Y. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J Natl Cancer Inst. 1992;84:113-8.
31. Jensen PB. Differential sensitivity patterns in small cell lung cancer cell lines: detection and circumvention of resistance to topoisomerase II targeting drugs. Dan Med Bull 1994; 41:475-88.
32. Pratesi G, Capranico G, Binaschi M. Relationships among tumor responsiveness, cell sensitivity, doxorubicin cellular pharmacokinetics and drug-induced DNA alterations in two human small-cell lung cancer xenografts. Int J Cancer 1990;46:669-74.
33. Tungekar MF, Gatter KC, Dunnill MS, Mason DY. Ki-67 immunostaining and survival in operable lung cancer. Histopathology 1991;19:545-50.
34. Schluter C, Duchrow M, Wohlenberg C. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 1993;123:513-22.
35. Keith WN, Tan KB, Brown R. Amplification of the topoisomerase II alpha gene in a non-small cell lung cancer cell line and characterisation of polymorphisms at the human topoisomerase II alpha and beta loci in normal tissue. Genes Chromosom Cancer 1992;4:169-75.
36. D'Andrea MR, Farber PA, Foglesong PD. Immunohistochemical detection of DNA topoisomerases IIa and lib compared with detection of Ki-67, a marker of cellular proliferation, in human tumors. Appl Immunohistochem 1994;2:177-85.
37. Duchrow M, Gerdes J, Schluter C. The proliferation-associated Ki-67 protein: definition in molecular terms. Cell Prolif 1994;27:235-42.
38. Verheijen R, Kuijpers HJ, van Driel R. Ki-67 detects a nuclear matrix-associated proliferation-related antigen. II. Localization in mitotic cells and association with chromosomes. J Cell Sci 1989;92:531-40.
39. Hsiang YH, Wu HY, Liu LF. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 1988;48:3230-5.
40. Heck MM, Hittelman WN, Earnshaw WC. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 1988;85:1086-90.
41. Bruderman I. Bronchogenic carcinoma. In: Baum GL, Wolinsky E, editors. Textbook of pulmonary diseases. Boston: Little, Brown and Company, 1989;1197-237.
42. Lokich J, Auerbach M, Essig L, Fryer J, Fryer D. Etoposide plus cisplatin followed by thoracic radiation for stage IIIB non-small cell lung cancer: MAOP study 2188. J Infus Chemother 1995;5:70-2.
43. Splinter T, Kok T, Kho S. A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer. Semin Oncol 1986;13:97-103.
44. Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 1992;52:1666-74.
45. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
46. Lowe SW, Bodis S, McClatchey A. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
47. Miller CW, Simon K, Aslo A. p53 mutations in human lung tumors. Cancer Res 1992;52:1695-8.
48. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-78.
49. D'Amico D, Carbone D, Mitsudomi T. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 1992;7:339-46.
50. Takahashi T, Suzuki H, Hida T, Sekido Y, Ariyoshi Y, Ueda R. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 1991;6:1775-8.
51. Milroy R, Plumb JA, Batstone P. Lack of expression of P-glycoprotein in 7 small cell lung cancer cell lines established both from untreated and from treated patients. Anticancer Res 1992;12:193-200.
52. Cole SP, Chanda ER, Dicke FP, Gerlach JH, Mirski SE. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 1991;51:3345-52.
53. Withoff S, Smit EF, Meersma GJ. Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay. Lab Invest 1994;71:61-6.
54. Mirski SE, Evans CD, Almquist KC, Slovak ML, Cole SP. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res 1993; 53:4866-73.
55. de Jong S, Zijlstra JG, de Vries EG, Mulder NH. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 1990;50:304-9.
56. Vassetzky YS, Gian-Carlo A, Gasser SM. DNA topoisomerase II mutations and resistance to anti-tumor drugs. Bioessays 1995;17:767-74.
57. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-6.
58. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
59. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992;71:543-6.